Biocon Limited announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Zentiva. Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
339.9 INR | +1.16% |
|
+9.91% | +36.15% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 03 | Biocon Limited Receives Approval from the U.S. Food and Drug Administration | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.15% | 4.8B | |
+18.38% | 125B | |
+13.56% | 108B | |
-7.39% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-13.78% | 16.37B | |
+1.65% | 13.58B | |
+28.21% | 11.66B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K